SecBot SecBot
425 ·Filed Jul 20, 2026

PSNL

Personalis, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001193125-26-308500
Rule 425 M&A communications
Actionable Insight ▲ Bullish

PSNL shares should trade near the $16.25 deal price with a small spread reflecting closing risk (shareholder vote, regulatory approvals, and the Tempus stock price floor of $46.00). Monitor for any competing bids, regulatory hurdles, or shareholder dissent. TEM shares may face modest dilution overhang given the stock consideration structure.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.34
T+0 close · Jul 20, 2026 · via day close
Latest settled
+18.82%
T+60 · $15.85
Vs SPY
+13.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $13.34entry
  2. T+1 · 4mo ago +0.75%α −0.08% · $13.44
  3. T+5 · 4mo ago −11.69%α −11.27% · $11.78
  4. T+20 · 3mo ago +4.12%α +0.00% · $13.89
  5. T+60 · 5w ago +18.82%α +13.98% · $15.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tempus AI (TEM) announced a definitive agreement to acquire Personalis (PSNL) for $16.25 per share in a stock transaction valued at $1.5 billion enterprise value, representing a 6% premium to the prior close and a 28% premium to the 30-day VWAP. The deal combines Personalis' MRD technology with Tempus' AI platform and commercial infrastructure, with closing expected in late 2026 or early 2027. Personalis also reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests, a 33% sequential volume increase.

Key Financial Metrics

Deal Value
$1.5B
Premium
6%
Deal Type
merger

Key Facts

  • Tempus to acquire Personalis for $16.25 per share, total enterprise value of $1.5 billion
  • Consideration is 100% stock with Tempus option to elect cash up to 50%
  • Premium of 6% to Friday's close and 28% to 30-day VWAP
  • Personalis reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests (+33% QoQ)
  • Closing expected late 2026 or early 2027, subject to shareholder and regulatory approvals
  • Transaction approved by both boards; Personalis conducted an 'exhaustive process'
  • MRD market described as a $20 billion opportunity

Financial Impact

$1.5 billion enterprise value acquisition at $16.25/share; Personalis Q2 preliminary revenue $22.4M

revenueenterprise valueshare price

Risk Factors

  • Personalis shareholders may not approve the merger
  • Regulatory approvals may be delayed or impose conditions
  • Tempus stock price falling below $46.00 gives Personalis termination right
  • Integration risks and potential failure to achieve synergies
  • Potential litigation related to the transaction

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-308500
Document: 0001193125-26-308500-index-headers.html0001193125-26-308500
Document: 0001193125-26-308500-index.html0001193125-26-308500
Document: 0001193125-26-308500.txt0001193125-26-308500

Track record

29 reports on PSNL

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
  3. Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
  4. Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
  5. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $15.55 Now $14.80 −4.82% settles Feb 3
  6. Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
  7. Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
  8. Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
  9. Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
  10. Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026